|
GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
|
US3578687A
(en)
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
|
US3819561A
(en)
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
|
JPS5313608B2
(da)
|
1972-06-16 |
1978-05-11 |
|
|
|
JPS5318013B2
(da)
|
1973-03-19 |
1978-06-13 |
|
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
|
DE69519300T2
(de)
|
1994-08-08 |
2001-05-31 |
Debiopharm S.A., Lausanne |
Stabiles arzneimittel enthaltend oxaliplatin
|
|
KR100463709B1
(ko)
|
1994-10-13 |
2005-08-04 |
위민스 앤드 칠드런스 호스피털 애드레이드 |
변형된불포화지방산
|
|
US5919816A
(en)
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
EP1025842B1
(en)
|
1997-10-30 |
2004-07-21 |
Morishita Jintan Co., Ltd. |
Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
|
|
HRP20020585B1
(hr)
|
1997-11-12 |
2013-02-28 |
Bayer Schering Pharma Aktiengesellschaft |
2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
|
|
US7795246B2
(en)
|
1998-08-06 |
2010-09-14 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
|
US6262029B1
(en)
|
1998-08-14 |
2001-07-17 |
Galenica Pharmaceuticals, Inc. |
Chemically modified saponins and the use thereof as adjuvants
|
|
KR20010101603A
(ko)
|
1999-01-20 |
2001-11-14 |
노왈드 |
이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
|
|
ATE384035T1
(de)
|
1999-04-01 |
2008-02-15 |
Esperion Therapeutics Inc |
Ether-verbindungen, zusammensetzungen und ihre verwendung
|
|
AU5319499A
(en)
|
1999-07-22 |
2001-02-13 |
Ivan L. Cameron |
Fatty acids to minimize cancer therapy side effects
|
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
|
AUPQ291499A0
(en)
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
|
IL139455A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
|
US20010037598A1
(en)
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
|
AU3846801A
(en)
|
2000-02-16 |
2001-08-27 |
Brigham & Womens Hospital |
Aspirin-triggered lipid mediators
|
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
|
DK1294658T3
(da)
|
2000-06-28 |
2005-06-27 |
Zambon Spa |
Fremgangsmåde til fremstilling af nitroalkener
|
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
|
DK1368022T3
(da)
|
2001-03-02 |
2007-10-01 |
Debiopharm Sa |
Anvendelse af en flaske indeholdende en oxaliplatinoplösning
|
|
EA007322B1
(ru)
|
2001-04-18 |
2006-08-25 |
Прометик Байосайенсиз, Инк. |
Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
|
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
|
EP1407767A4
(en)
|
2001-06-18 |
2007-01-24 |
Yamada Sachiko |
AGONIST MEDICINAL PREPARATIONS PPAR $ G (G)
|
|
CN1571672A
(zh)
|
2001-08-17 |
2005-01-26 |
匹兹堡大学 |
给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病
|
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
|
HN2002000317A
(es)
|
2001-11-02 |
2003-05-21 |
Pfizer |
Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
|
|
BR0213817A
(pt)
|
2001-11-02 |
2004-10-19 |
Pfizer Prod Inc |
Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
|
|
JP4652685B2
(ja)
|
2001-11-06 |
2011-03-16 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
|
|
GB2388111A
(en)
|
2002-05-01 |
2003-11-05 |
Bayer Ag |
Novel imidazotriazinone compounds
|
|
US6684626B1
(en)
|
2002-07-30 |
2004-02-03 |
General Electric Company |
Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
|
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
|
JP2006503014A
(ja)
|
2002-08-20 |
2006-01-26 |
プロテミックス コーポレイション リミティド |
剤形及び関連する治療法
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
US7326421B2
(en)
|
2002-10-21 |
2008-02-05 |
Kensey Nash Corporation |
Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
|
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7935365B2
(en)
|
2003-10-22 |
2011-05-03 |
Enzymotec, Ltd. |
Glycerophospholipids for the improvement of cognitive functions
|
|
EP1686998A1
(en)
|
2003-10-31 |
2006-08-09 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
|
EP1718602A4
(en)
|
2004-01-30 |
2007-12-12 |
Peplin Biolipids Pty Ltd |
THERAPEUTIC AND CARRIER MOLECULES
|
|
CA2563533C
(en)
|
2004-04-15 |
2013-10-01 |
Shmuel A. Ben-Sasson |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7776916B2
(en)
|
2004-04-28 |
2010-08-17 |
The Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
|
CN103223160B
(zh)
|
2004-07-19 |
2015-02-18 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
JPWO2006011397A1
(ja)
|
2004-07-27 |
2008-05-01 |
興和株式会社 |
糖尿病の予防または治療のための薬剤
|
|
EA010802B1
(ru)
|
2004-11-19 |
2008-12-30 |
Мартек Байосайенсиз Корпорейшн |
Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
|
|
WO2006058250A2
(en)
|
2004-11-24 |
2006-06-01 |
Spi Pharma, Inc. |
Orally disintegrating compositions
|
|
AU2011202664B2
(en)
|
2004-12-08 |
2012-04-05 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
|
US20070032420A1
(en)
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
WO2007028051A2
(en)
|
2005-09-02 |
2007-03-08 |
Abbott Laboratories |
Novel imidazo based heterocycles
|
|
GB0522569D0
(en)
|
2005-11-04 |
2005-12-14 |
Univ Bath |
Biocompatible drug delivery device
|
|
TW200815436A
(en)
|
2006-05-30 |
2008-04-01 |
Elbion Ag |
4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
|
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
|
US20090264483A1
(en)
|
2006-07-14 |
2009-10-22 |
Cedars-Sinai Medical Center |
METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
|
|
MX2009000657A
(es)
|
2006-07-19 |
2009-05-28 |
Resolvyx Pharmaceuticals Inc |
Composiciones y metodos para el tratamiento de mucositis.
|
|
US7947577B2
(en)
|
2006-09-08 |
2011-05-24 |
Tokuyama Corporation |
Method and apparatus for producing group III nitride
|
|
WO2008072779A1
(ja)
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
キノキサリン誘導体
|
|
JPWO2008072778A1
(ja)
*
|
2006-12-13 |
2010-04-02 |
あすか製薬株式会社 |
尿路系疾患の処置剤
|
|
US20110190389A1
(en)
|
2007-02-20 |
2011-08-04 |
Linda Arterburn |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
PT2152712E
(pt)
|
2007-05-11 |
2012-02-29 |
Pfizer |
Compostos amino-heterocíclicos
|
|
DE102007032349A1
(de)
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
|
EP2180787B1
(en)
|
2007-08-01 |
2013-10-30 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Nitro oleic acid modulation of type ii diabetes
|
|
CA2699483A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for modulating immune function
|
|
CN102066924B
(zh)
|
2008-04-18 |
2013-03-27 |
犹他大学研究基金会 |
使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
|
|
WO2009134383A2
(en)
|
2008-05-01 |
2009-11-05 |
Complexa Inc. |
Vinyl substituted fatty acids
|
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
|
EP2299997A4
(en)
|
2008-06-19 |
2012-01-11 |
Univ Utah Res Found |
USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
ES2964764T3
(es)
|
2008-07-29 |
2024-04-09 |
Nerviano Medical Sciences Srl |
Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
US8933255B2
(en)
|
2008-12-31 |
2015-01-13 |
Nitromega Corp. |
Nutraceuticals containing nitro fatty acids
|
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
|
WO2011011712A1
(en)
|
2009-07-24 |
2011-01-27 |
Concert Pharmaceuticals, Inc. |
Substituted imidazotriazines
|
|
EP2459510A4
(en)
|
2009-07-29 |
2013-08-07 |
Phenomenome Discoveries Inc |
HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
|
|
US9066902B2
(en)
|
2009-07-31 |
2015-06-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fatty acids as anti-inflammatory agents
|
|
US9260432B2
(en)
|
2009-09-02 |
2016-02-16 |
Concert Pharmaceuticals, Inc. |
Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
|
|
WO2011030351A2
(en)
|
2009-09-03 |
2011-03-17 |
Rubicon Research Private Limited |
Taste - masked pharmaceutical compositions
|
|
EP2483233A4
(en)
|
2009-10-02 |
2013-08-14 |
Complexa Inc |
HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
|
|
KR20120130078A
(ko)
|
2009-11-09 |
2012-11-28 |
메디비르 아베 |
신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
WO2011113507A2
(en)
|
2010-03-15 |
2011-09-22 |
Ulrich Dietz |
Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
|
|
CN102843922B
(zh)
|
2010-05-13 |
2015-12-16 |
尼特罗米加公司 |
硝基脂肪酸–认知减退的神经保护和/或抑制
|
|
WO2012006014A2
(en)
|
2010-06-28 |
2012-01-12 |
Complexa, Inc. |
Multi-component pharmaceuticals for treating diabetes
|
|
EP3181566A1
(en)
|
2010-09-20 |
2017-06-21 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2013028501A1
(en)
|
2011-08-19 |
2013-02-28 |
The University Of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
WO2013051639A1
(ja)
|
2011-10-07 |
2013-04-11 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピラゾロキノリン誘導体
|
|
HK1211023A1
(zh)
*
|
2011-10-10 |
2016-05-13 |
H. Lundbeck A/S |
具有咪唑并吡嗪骨架pde9i
|
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
DE102012008730A1
(de)
|
2011-12-02 |
2013-06-06 |
Dr. Budz GmbH |
Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
|
|
HK1199879A1
(en)
|
2012-01-26 |
2015-07-24 |
H.隆德贝克有限公司 |
Pde9 inhibitors with imidazo triazinone backbone
|
|
EP2809662B1
(en)
|
2012-02-01 |
2018-07-04 |
City of Hope |
Ribonucleotide reductase inhibitors and methods of use
|
|
CA2863765A1
(en)
|
2012-02-03 |
2013-08-08 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Fatty acids as anti-inflammatory agents
|
|
US10435367B2
(en)
|
2013-03-14 |
2019-10-08 |
City Of Hope |
Indirubin derivatives, and uses thereof
|
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
|
US10058688B2
(en)
|
2012-05-09 |
2018-08-28 |
Massachusetts Institute Of Technology |
Medicament, method, and drug delivery device for treatment of ovarian cancer
|
|
ES2902833T3
(es)
|
2012-08-31 |
2022-03-30 |
Taris Biomedical Llc |
Sistemas y métodos de administración de fármacos para el tratamiento de cáncer de vejiga que comprenden oxaliplatino
|
|
US20140271844A1
(en)
|
2013-03-15 |
2014-09-18 |
Nitromega Corp. |
Compositions containing nitro fatty acids
|
|
EP2983730B1
(en)
|
2013-04-10 |
2019-10-16 |
Massachusetts Institute of Technology |
Local drug delivery devices and methods for treating cancer
|
|
EP2994165A4
(en)
|
2013-05-10 |
2017-01-04 |
Nitromega Corp. |
Nutritional or dietary supplements containing fatty acids and nitrite
|
|
US20150051283A1
(en)
|
2013-06-14 |
2015-02-19 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
CN105744983B
(zh)
|
2013-08-12 |
2019-12-27 |
纳米医学系统公司 |
用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
|
|
WO2015073527A1
(en)
|
2013-11-12 |
2015-05-21 |
Complexa, Inc. |
Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
|
|
WO2015185499A1
(en)
|
2014-06-06 |
2015-12-10 |
H. Lundbeck A/S |
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
|
WO2016044446A2
(en)
|
2014-09-17 |
2016-03-24 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
|
US20180092948A1
(en)
|
2015-04-02 |
2018-04-05 |
Aobiome Llc |
Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
|
|
LT3865484T
(lt)
|
2015-07-07 |
2024-02-12 |
H. Lundbeck A/S |
Pde9 inhibitorius su imidazopirazinono karkasu, skirtas periferinių ligų gydymui
|
|
IL297844A
(en)
|
2015-10-02 |
2023-01-01 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|
|
PL3416964T3
(pl)
|
2016-02-19 |
2021-10-18 |
Phoenix Molecular Designs |
Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
|
|
IL295973A
(en)
|
2016-07-06 |
2022-10-01 |
H Lundbeck As |
pde9 inhibitors for the treatment of peripheral diseases
|
|
US11370795B2
(en)
|
2017-05-26 |
2022-06-28 |
Imara Inc. |
Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
|
|
HRP20240363T1
(hr)
|
2018-05-25 |
2024-06-07 |
Cardurion Pharmaceuticals, Inc. |
Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona
|
|
WO2020047311A1
(en)
|
2018-08-31 |
2020-03-05 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
|
CA3136128A1
(en)
|
2019-04-05 |
2020-10-08 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
|
EP3965768A1
(en)
|
2019-05-07 |
2022-03-16 |
Imara Inc. |
Pde9 inhibitors for treating thalassemia
|
|
WO2022036111A1
(en)
|
2020-08-13 |
2022-02-17 |
Imara Inc. |
Methods and compositions for treating sickle cell disease
|
|
MX2023004881A
(es)
|
2020-10-27 |
2023-06-16 |
Cardurion Pharmaceuticals Inc |
Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca.
|